Until there is more data to support the outcomes of using telemedicine, payers will be more cautious about getting into reimbursing for the technology, said Anne Schmidt, MD, associate medical director at Blue Cross and Blue Shield of Alabama.
Until there is more data to support the outcomes of using telemedicine, payers will be more cautious about getting into reimbursing for the technology, said Anne Schmidt, MD, associate medical director at Blue Cross and Blue Shield of Alabama.
Transcript (slightly modified)
Why has there seemed to be a reluctance to dive into reimbursing telemedicine?
As far as reimbursement for telemedicine, I think that as payers we're all looking for new ways to optimize health outcomes. So I'm not sure that I'd say "reluctance" to dive into telemedicine—as payers, again, we are more conservative than some other groups that are out there. And we realize that the better outcomes that we can promote for our members—physicians, patients—the better off we all will be: financially, patients will have better outcomes; physicians will have better satisfaction—job satisfaction—and better outcomes for themselves.
So I think what we're looking for is more evidence right now. More data to just support the fact that there are better outcomes, and I think Medicare's NDPP [National Diabetes Prevention Program] and the fact that they are now going to reimburse for that gives us some data to support that.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More